Progression-free and overall survival for high-risk patients with relapsed or refractory multiple myeloma (RRMM) who received carfilzomib-based regimens
PFS in KRd patients: ≥CR responders versus | Download Scientific Diagram
Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation. - ppt download
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation. - ppt download
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials - ScienceDirect
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR - ScienceDirect
Myeloma Update -- Part 1: Carfilzomib and Panobinostat
ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma - ScienceDirect
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
How to Treat High-Risk Myeloma at Diagnosis and Relapse | American Society of Clinical Oncology Educational Book
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia
Carfilzomib in multiple myeloma
Elotuzumab - A Closer Look At The ELOQUENT-2 Clinical Trial Results
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Carfilzomib in multiple myeloma
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Interim Results of ASPIRE Trial | Int'l Myeloma Fndn
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Takeda Oncology on Twitter: "Multiple #myeloma may be the most common, but DYK there are several other forms of myeloma? Take action, learn more https://t.co/aDKofURa4c https://t.co/aFizSxMTn0" / Twitter
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
